Skip Navigation


NDT Advance Access originally published online on July 23, 2009
Nephrology Dialysis Transplantation 2009 24(11):3284-3285; doi:10.1093/ndt/gfp368
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
24/11/3284    most recent
gfp368v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Krüger, T.
Right arrow Articles by Floege, J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Krüger, T.
Right arrow Articles by Floege, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press [on behalf of ERA-EDTA]. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org


Coumarin use in dialysis patients with atrial fibrillation—more harm than benefit?

Thilo Krüger and Jürgen Floege

Division of Nephrology and Clinical Immunology, RWTH University of Aachen, Germany

Correspondence and offprint requests to: Jürgen Floege; E-mail: juergen.floege@rwth-aachen.de

Keywords: atrial fibrillation; haemodialysis; warfarin

The first 10% of the full text of this article appears below.

Atrial fibrillation (AF) is the most common arrhythmia in haemodialysis (HD) patients. In the United States Renal Data System (USRDS) report, the prevalence in the American HD population is given as ~10% [1]. The major risk associated with AF is the development of intraatrial thrombi with subsequent stroke or peripheral embolic events. Oral anticoagulation with coumarins is often initiated in AF patients, but its benefits must be weighed against bleeding complications. The CHADS2 score, which is part of the AHA (American Heart Association) and . . . [Full Text of this Article]



   Data on coumarin use in HD patients with AF are scarce and inconclusive
 


   Coumarin therapy and vascular calcification
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?